PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility.

07:00 EST 12th February 2020 | BioPortfolio

Summary of "PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility."

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel class of non-statin lipid lowering therapy that reduce LDL-cholesterol by 50 - 60%. PCSK9 inhibitors decrease LDL-cholesterol by preventing intracellular degradation of LDL receptors; subsequently, a greater number of LDL-receptors are available on the cell surface to extract circulating LDL.


Journal Details

This article was published in the following journal.

Name: Endocrine, metabolic & immune disorders drug targets
ISSN: 2212-3873


DeepDyve research library

PubMed Articles [26371 Associated PubMed Articles listed on BioPortfolio]

PCSK9 and inflammation: Role of shear stress, pro-inflammatory cytokines and LOX-1 4.

PCSK9 degrades LDL receptors and subsequently increases serum LDL-cholesterol. Clinical trials show that inhibition of PCSK9 efficiently lowers LDL-cholesterol levels and reduces cardiovascular events...

Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes.

PCSK9 is an endogenous inhibitor of the LDL receptor pathway. Recently, Mendelian randomization studies have raised a doubt about the diabetogenic risk of PCSK9 inhibitors. Here, we assessed the relat...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.

We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9.

A Review of PCSK9 Inhibitors and their effects on cardiovascular disease.

Cardiovascular disease remains the leading cause of morbidity and mortality in the world, with elevated low density lipoprotein-cholesterol (LDL-C) levels as a major risk factor. Lower levels of LDL-C...

Targeting PCSK9: Implications for basic science and upcoming challenges.

Low-density lipoprotein cholesterol (LDL-C) plays a central role in the progression of atherosclerosis. Statin therapy for lowering LDL-C reduces the risk of atherosclerotic cardiovascular disease and...

Clinical Trials [5180 Associated Clinical Trials listed on BioPortfolio]

PCSK9 Inhibitors in the Progression of Aortic Stenosis

Investigators plan evaluate whether PCSK9 inhibitors, a medication that can lower lipoprotein(a) and control dyslipidemia, can inhibit the progression of aortic stenosis, through a randomi...

The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)

cvMOBIUS is a North American registry of patients with ASCVD aimed at understanding patterns of care in ASCVD while evaluating the real world effectiveness of PCSK9 inhibitors.

Interest of Plasmatic Concentration Dosage of PCSK9 in Coronary Syndrome

PCSK9 (Proprotein convertase subtilisin kexin type 9) is a proconvertase playing the key-role in LDL-Cholesterol (LDLC) metabolism inhibiting the LDL receptor by a post-transcriptional way...

Treatment of Severe Infection With Antihyperlipidemia Drug

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors increase LDL receptors by decreasing its degradation. In sepsis the pathogenic substances, endotoxin, lipoteichoic acid, phospho...

Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged over the past decade as a post-transcriptional regulator of the LDL receptor (LDL-R). PCSK9 acts as an endogenous natural ...

Medical and Biotech [MESH] Definitions

The internal resistance of the BLOOD to shear forces. The in vitro measure of whole blood viscosity is of limited clinical utility because it bears little relationship to the actual viscosity within the circulation, but an increase in the viscosity of circulating blood can contribute to morbidity in patients suffering from disorders such as SICKLE CELL ANEMIA and POLYCYTHEMIA.

Works consisting of studies determining the effectiveness or utility of processes, personnel, and equipment.

One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors) used for hypertension. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat.

One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.

Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.

Quick Search

DeepDyve research library

Relevant Topics

Cholesterol is a waxy steroid metabolite found in the cell membranes and transported in the blood plasma. It is an important structural component of mammalian cell membranes, where it is establishes proper membrane permeability and fluidity. Cholesterol ...

Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Increased cholesterol levels have been as...

Searches Linking to this Article